Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), a clinical-stage innovative drug development ...
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / ...
Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...
Zacks Investment Research on MSN
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche RHHBY announced positive data from the late-stage lidERA Breast Cancer study on pipeline candidate giredestrant.
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research.
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Rahway, New Jersey Wednesday, November 19, 2025, 10:00 Hrs [IST] ...
Traditionally, developing a new drug can take over a decade, but AI technology is changing that timeline. Major pharmaceutical companies like Pfizer and AstraZeneca are leveraging AI to accelerate the ...
Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback